Geron Corporation (GERN) Announces Grant of Stock Options; Scotiabank Reiterates 'Hold' Rating

With significant hedge fund interest and a share price under $10, Geron Corporation (NASDAQ:GERN) secures a spot on our list of the 11 Best Single Digit Stocks to Buy According to Hedge Funds.

Geron Corporation (NASDAQ:GERN) announced the grant of stock options on August 8, 2025. The options to purchase 11 million shares are offered to newly appointed President and CEO Harout Semerjian at an exercise price of $1.30, the company’s closing share price on August 8. Furthermore, the options incentivize long-term alignment with a 10-year term, along with structured vesting over four years.

This development takes place amid mixed Wall Street sentiment. On August 7, Scotiabank reiterated its ‘Hold’ rating on Geron Corporation (NASDAQ:GERN) with a $1.50 price target. Meanwhile, Barclays also maintained its ‘Buy’ rating, but with a higher $4.00 target. Previously, H.C. Wainwright maintained a ‘Hold’ rating on the company on July 29. The analyst sentiment appears divided around the company’s short-term outlook, awaiting the commercial rollout of its telomerase inhibitor RYTELO and the potential strategic direction under Semerjian’s leadership.

Geron Corporation (NASDAQ:GERN), a biopharmaceutical company, focuses on developing oncology therapeutics for transfusion-dependent anemia. It is included in our list of the Best Single Digit Stocks.

While we acknowledge the potential of GERN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Gold Penny Stocks to Buy According to Hedge Funds and 11 Best Rebound Stocks to Buy According to Hedge Funds.

Disclosure: None.